GLP-1semaglutideglp-1 receptor agonistsobesityolder adults

Israeli cohort links sustained GLP-1 use to BMI gains in older adults

Among 13,387 Clalit patients aged 65 and over without diabetes, diabetes diagnoses occurred in 2.5% of sustained users versus 5.3% of minimal users.

By Maren Holt · Senior Reporter, GLP-1

Oct 21 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01BMI category improved in 55% of patients with three or more GLP-1 receptor agonist dispensations versus 30% with one or two (median change -8% vs -2%); adjusted odds ratio 2.77 (95% CI 2.51-3.06).
02Data address an older, non-diabetic obesity population that is under-represented in incretin trials, including prediabetes reversal in 65% of sustained users versus 37%.
03Retrospective and observational: the authors state the findings describe changes after initiation and are not a proven causal treatment effect, with confounding by adherence likely.

From the source

Sustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes
Diabetes, obesity & metabolism · 2026 Oct 22 · Zaritsky R, Elior N, Razi T et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42919108/